Global Institute Of Stem Cell Therapy And Research

Category

News

Journal of Stem Cell Research & Therapeutics (2475-5540)

Dear Dr. Anand S Srivastava,

Hope you are doing well.

At first, I sincerely apologize if am disturbing you in your hectic schedule.

We are glad to let you know that Journal of Stem Cell Research & Therapeutics (2475-5540) have successfully released the former issues in 2016.

Moreover we are running with Volume 2 issue 2 and we are in need of one article to accomplish this issue. In fact we have gone through your eminent articles in online and my desire is to fulfill the issue with your article.

Hence I humbly request you to submit your manuscript (Review/Mini review/Case Report) at the earliest. Your prompt submission will help me to release the issue in time and will impact my ranking too.

Hope you will understand us and look forward to receive your manuscript as early as possible.

Await your reply.

Best Regards,

Melissa Hawkins

Hi Dr. Anand S. Srivastava,
Greetings from Journal of Stem Cell Research

Journal of Stem Cell Research is successfully publishing quality open access articles with the support from scientists like you. We are aware of your reputation for quality of research and trustworthiness in the field of “Stem Cell Research” and that is why you have been inviting to join as an Editorial Board Member of our Journal of Stem Cell Research.

Please send us your updated CV, biography, research interest and recent passport size photo. 

Feel free to contact us for further assistance. We are ready to serve you.
We look forward for a long lasting scientific relationship with you.

Sincerely,
Rapture D
editor.jscr@opastjournals.com

Managing Editor

Overland Park, KS
US

Invitation from Journal of Clinical Research and Trial to Submit a Manuscript

Dear Anand S,

Greetings from Clinical Research and Trials (CRT) !

This is a special Request regarding manuscript contribution to our Journal. We will be glad if you can submit your manuscript along with cover letter at clinicaltrials@oatextjournals.com

We would like to inform you regarding our Annual Membership Program. Keeping in view your tremendous contribution to the scientific field, we wish to offer you free membership.

Kindly let us know your opinion in this regard. So, that we will send you more details regarding individual membership and other benefits.

Awaiting for your positive response.

Have a great day

Best Regards
Regina Mathew
Editorial Coordinator
Office Gold, building 3 Chiswick Park
Greater London, W4 5YA
United Kingdom

FDA-Approved Study Uses Adipose Stem Cells for Treatment of Shoulder Injuries

 

Sanford Health is conducting the first clinical trial approved by the FDA to treat injured shoulders using patients’ adipose stem cells.

“A number of studies have demonstrated that fat-derived stem cells have great healing potential by boosting the immune system and helping the natural healing process,” Jason Hurd, MD, a principal investigator of the study and orthopedic surgeon at Sanford Orthopedics & Sports Medicine in Sioux Falls, South Dakota, told Orthopedics Today. “Also, isolation of fat tissue is less invasive than isolation of other pools of stem cells, such as those found in the bone marrow, which might include a more complicated surgical procedure.”

Hurd and Mark Lundeen, MD, the other lead investigator of the study, began the trial in December to determine whether adipose stem cells, extracted from a patient’s abdominal fat, could repair partial thickness tears in the rotator cuff, according to a press release from Sanford Health. Investigators hypothesize that injecting the stem cells into the injured area could activate the patient’s body’s natural healing process, accelerate healing and regenerate tissue.

“Sanford Health physicians and scientists are the first in the country to work with the FDA on a trial using adipose stem cells in rotator cuff tears, which are common,” Kelby Krabbenhoft, president and chief executive officer of Sanford Health, said in the release. “We have been monitoring the potential of these types of stem cells for some time. In Europe, adipose stem cells have been used as a therapy option for damaged tissues and are approved to carry the CE mark, which signifies that a product has been assessed by and meets certain safety, health and environmental protection requirements in the European Union.” ‒ by Monica Jaramillo

Source : https://goo.gl/VLSG84

Tackling Parkinson Disease Through Cell Rejuvenation

 

It started with a hand tremor that was more pronounced when typing. At first, it just interfered with hobbies. But it got progressively worse. Soon handwriting was illegible. The simple act of walking became difficult. Memory problems and an urgency to urinate finally send the patient to the doctor, for the cruel diagnosis: Parkinson disease, a condition resulting from cell degeneration in the brain.

There are other disorders like it, Alzheimer for example, that share an important trait — they arise when the body’s aging cells stop doing what they are supposed to do.

For many of these conditions, there are no cures, just treatments designed to slow the progression, where possible. But we may soon be looking at new treatment options developed through mitochondrial genetics and the study of aging.

The degeneration of aging cells is related to abnormalities in power plant organelles called mitochondria. In normal cell function, these mitochondria deteriorate over time and are eventually ejected from the cell.

Over the past few decades, researchers have discovered evidence that mitochondria become dysfunctional because of mutations in their DNA. (Mitochondrial DNA, or mtDNA, is separate from the DNA comprising the chromosomes of a cell’s nucleus.) The dysfunction, in turn, is connected to cellular aging and the onset of degenerative diseases. There are two new developments in this area of research.

Tackling Parkinson Disease Through Cell Rejuvenation

The first involves the realization that while certain mtDNA mutations contribute to the disruption of mitochondrial function, there are mutations in other mitochondrial genes that prevent the cell from removing the dysfunctional mitochondria. Essentially, the cell loses the ability to perform its own quality control.

“We know that increased rates of mtDNA mutation cause premature aging,” said Bruce Hay, Professor of biology and biological engineering at the California Institute of Technology. “This, coupled with the fact that mutant mtDNA accumulates in key tissues such as neurons and muscle that lose function as we age, suggests that if we could reduce the amount of mutant mtDNA, we could slow or reverse important aspects of aging.”

This brings us to the second major development relevant to mitochondria in disease — that genetic technology is now at a point where the targeted removal of the problem mitochondrial genes can become the basis for clinical intervention. This is the implication of research that Hay and colleagues both at Caltech and the University of California at Los Angeles have described in a paper published recently in the prestigious journal Nature Communications.

Fixing body tissues by knocking out genes that prevent bad mitochondrial from being ousted in a timely fashion might sound like science fiction, but that’s where things are going and it’s part of a growing trend of what’s being described as mitochondrial medicine.

With degenerative diseases, the standard treatment involves the replacement of the physiologic function of the diseased tissue. In Parkinson disease, this often means replacing a neurotransmitter called dopamine in a part of the brain where it’s lacking, due to degeneration of dopamine-making cells. While this works well in the initial stages of the disease, it gradually becomes less effective.

There are two new strategies. One is to regenerate the failing tissue using stem cells. The other is gene therapy in which the patients’ own brain cells are given the ability to make something they don’t usually make. For instance, the part of the brain that usually receives dopamine is given the ability to make its own dopamine.

Neurosurgeons are actually quite good at injecting agents into specific regions of the brain with extreme precision. This is why gene therapy and stem cell therapy are showing promise. But this also means there’s a capability to deliver agents that could affect mitochondria. It means that it should be possible in the near future to manage degenerative diseases with a third advance treatment prong: restoring the cell’s ability to expel failing mitochondria.

Source : https://goo.gl/JdfS9M

Make An Enquiry

We are here to help you

Call Us +91-7043008890
WordPress Video Lightbox